Stay updated on Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.

Latest updates to the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page
- Check6 days agoChange DetectedRemoval of metadata topics 'Head and neck squamous cell carcinoma' and related terms like 'MedlinePlus Genetics' from the page may affect indexing and search filters, but does not change the trial content or eligibility details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check14 days agoChange DetectedAdds contextual tags such as 'Head and neck squamous cell carcinoma' and related topic links (MedlinePlus Genetics) and updates revision notes; removes a government funding notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding lapse and NIH Clinical Center operations, and updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check28 days agoChange DetectedThese are minor UI and metadata updates, including a new 'Show glossary' option, a new 'Last Update Submitted that Met QC Criteria' label, the addition of 'No FEAR Act Data', and the new 'Revision: v3.4.0' tag (with corresponding removals of 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with Ohio as a study site and updated the revision to v3.3.3. Removed items include HHS Vulnerability Disclosure, Head and neck squamous cell carcinoma, MedlinePlus Genetics, and Ohio Locations.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Post-op Radiotherapy in CSCC Clinical Trial page.